SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-23-029603
Filing Date
2023-08-21
Accepted
2023-08-21 16:03:45
Documents
61
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1568119
2 ex31-1.htm EX-31.1 19093
3 ex31-2.htm EX-31.2 19240
4 ex32-1.htm EX-32.1 10685
  Complete submission text file 0001493152-23-029603.txt   6714248

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE zvsa-20230630.xsd EX-101.SCH 45795
6 XBRL CALCULATION FILE zvsa-20230630_cal.xml EX-101.CAL 51310
7 XBRL DEFINITION FILE zvsa-20230630_def.xml EX-101.DEF 238377
8 XBRL LABEL FILE zvsa-20230630_lab.xml EX-101.LAB 355032
9 XBRL PRESENTATION FILE zvsa-20230630_pre.xml EX-101.PRE 305365
55 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1103343
Mailing Address 217 W. MAIN STREET SOMERVILLE NJ 08876
Business Address 217 W. MAIN STREET SOMERVILLE NJ 08876 908-370-5102
ZyVersa Therapeutics, Inc. (Filer) CIK: 0001859007 (see all company filings)

IRS No.: 862685744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41184 | Film No.: 231189122
SIC: 2834 Pharmaceutical Preparations